Ralinepag

Description	Ralinepag, also known as APD-811, is an orally available agonist of the prostacyclin (IP) receptor, is an investigational drug candidate internally discovered and developed by Arena and intended for the treatment of vasospastic diseases, such as Pulmonary Arterial Hypertension. Ralinepag has the potential to mimic prostacyclin, the major product of cyclooxygenase in macrovascular endothelium, which elicits a potent vasodilation and inhibition of platelet aggregation when binding to this receptor.
Pathways	GPCR/G Protein
Targets	Prostaglandin Receptor

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.